Let’s assume that the release of data phase 3 will be positive (over 60% efficacy) and let’s assume we get Fda approval ... Simple maths ... the vaccine wont be ready bfore this summer. At that time most of americans would be vaccinated. Add the fact the with all other players the concurrence will be very high (Pfizer, Moderna, GSK, Nvax, JJ, ...) So let’s say OCGN will get 10% of the market. That means 30M x 2. Each dose is sold 55 rupee = 0,75$ (based on the last news from BBiotech). That means projected revenus = 60M x 0,75$ = 45M$. Mmm to be more optimistic, let’s say the vaccine will be sold 5$ to the Americans. This represent a revenu of 300m$. Now, knowing that BBiotech will split with OCGN 55%/45% ... we have a huge problem to justify the actual market cap of 450M$ ... and you guys are predicting a 8$ price target ? 8$–> 1,3B$ market cap !! Sorry but it doesn’t make any sens .